European Coronary Stent Market to Decline to $490 Million by 2016, Despite Growth in Number of Procedures
Recent innovations in DES stents show promise. Biodegradable polymer drug-eluting stents, for example, offer a better safety profile than durable-polymer drug-eluting stents, as late-stent thrombosis is largely attributed to the polymer that binds the drug to the stent. In biodegradable polymer stents, a polymer controls drug release but then disappears, leaving a bare metal stent. Examples of stents with biodegradable polymers are Biosensors Internationals BioMatrix, Terumo Medicals Nobori, Sahajanand Medical Technologies Supralimus and Boston Scientifics fourth generation Synergy stent, which is still in development.
In contrast to bioabsorbable polymer stents, which still leave behind a bare metal stent, bioresorbable vascular scaffolds disappear completely, with the promise of vessel wall regrowth. A number of companies are working on scaffold products, including Abbott Vascular with ABSORB, REVA Medical with ReZolve, OrbusNeich and BIOTRONIK. Bioresorbable scaffolds were soft launched in 2011, and a full launch is expected across Europe by the end of 2012.
"These bioresorbable devices have the potential to revolutionize the market," said MRG Principal Analyst Karene Dumoulin. "They do need to demonstrate that they yield a decrease in the occurrence of late stent thrombosis or provide other advantages not available with current DES on the market, such as complete vascular restoration and motion, which is promised by Abbott Vasculars ABSORB device."
Millennium Research Groups European Markets for Interventional Cardiology Devices 2012 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices, and intravascular imaging catheters and pressure guidewires sold in France, Germany, Italy and the United Kingdom.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
Posted by Sean Fenske, Editor-in-Chief, MDT